rhVEGF165 delivered in a porous β‐tricalcium phosphate scaffold accelerates bridging of critical‐sized defects in rabbit radii
Source abstract
Abstract
Abstract Segmental bone defects are a common obstacle in major orthopedic procedures, and the treatment of these defects remains a challenging clinical problem. Bone tissue engineering has been attracting much attention in recent years. We evaluated the ability of the specific combination of 3 μg rhVEGF165 with a novel porous β‐tricalcium phosphate (β‐TCP) scaffold coated with fibrin sealant (FS) to facilitate bone regeneration. Unilateral 15‐mm long critical‐sized defects were prepared in the radial diaphysis of rabbits and treated with rhVEGF165/FS/scaffold or FS/scaffold. Healing of the defects was assessed at 4, 8, and 12 weeks, radiologically, histologically, and biomechanically. The results of the study demonstrated that the critical‐sized defects in the midshaft of the rabbit radius, treated with rhVEGF165 incorporated in porous β‐TCP scaffold by FS, can be completely bridged by cortical bone in 12 weeks. The bone marrow space was also reformed histologically and radiologically at 12 weeks postsurgery in the rhVEGF165‐treated group. Furthermore, biomechanical examination demonstrated that the segmental bone defects were not only radiologically and histologically repaired but were also mechanically repaired. Interestingly, none of the defects was completely repaired at 12 weeks following treatment with FS/scaffold without rhVEGF165. A solution‐driven process is likely the predominant mechanism of accelerating biodegradation of the β‐TCP scaffold in the presence of rhVEGF165; furthermore, cell‐mediated phagocytosis also contributes to biodegradation of the biomaterials. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Periodontal Regeneration and Treatments · Bone fractures and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. 10.5435/00124635-200401000-0000510.5435/00124635-200401000-00005 ↗
2. 10.5435/00124635-200501000-0001010.5435/00124635-200501000-00010 ↗
3. 10.1016/S0736-0266(02)00205-X10.1016/S0736-0266(02)00205-X ↗
4. 10.1016/j.biopha.2006.07.00410.1016/j.biopha.2006.07.004 ↗
5. 10.1126/science.849352910.1126/science.8493529 ↗
6. 10.1038/7944910.1038/79449 ↗
7. 10.1016/j.orthres.2004.03.00910.1016/j.orthres.2004.03.009 ↗
8. 10.1016/j.biomaterials.2003.09.00710.1016/j.biomaterials.2003.09.007 ↗
9. 10.1210/edrv.18.1.028710.1210/edrv.18.1.0287 ↗
10. 10.1038/946710.1038/9467 ↗
11. 10.1359/JBMR.05070110.1359/JBMR.050701 ↗
12. 10.1016/S8756-3282(01)00690-110.1016/S8756-3282(01)00690-1 ↗
13. 10.1177/15440591040830030410.1177/154405910408300304 ↗
14. 10.1073/pnas.15232409910.1073/pnas.152324099 ↗
15. 10.2106/00004623-200100002-0000110.2106/00004623-200100002-00001 ↗
16. 10.2106/JBJS.E.0100610.2106/JBJS.E.01006 ↗
17. 10.1016/S0142-9612(01)00119-310.1016/S0142-9612(01)00119-3 ↗
18. 10.1007/s00776005016310.1007/s007760050163 ↗
19. 10.1089/ten.2004.10.183010.1089/ten.2004.10.1830 ↗
20. 10.1302/0301-620X.89B1.1835010.1302/0301-620X.89B1.18350 ↗
21. Preparation of porous cell scaffolds of poly(L‐lactic acid) and poly(L‐lactic‐co‐glycolic acid) and the measurement of their porosity
22. Preparation of porous β‐tricalcium phosphate scaffold with high interconnection
23. 10.1182/blood.V96.12.377210.1182/blood.V96.12.3772 ↗
24. Iodination of vascular endothelial growth factor and analysis of its biological activity
25. 10.1016/S0168-3659(01)00266-810.1016/S0168-3659(01)00266-8 ↗
26. 10.1016/j.bone.2007.06.01810.1016/j.bone.2007.06.018 ↗
27. 10.2106/00004623-199712000-0000310.2106/00004623-199712000-00003 ↗
28. 10.1016/S0142-9612(02)00153-910.1016/S0142-9612(02)00153-9 ↗
29. 10.1002/(SICI)1097-4636(199824)43:4<365::AID-JBM4>3.0.CO;2-610.1002/(SICI)1097-4636(199824)43:4<365::AID-JBM4>3.0.CO;2-6 ↗
30. 10.3109/0284431820902621410.3109/02844318209026214 ↗
31. 10.1002/jbm.a.1007010.1002/jbm.a.10070 ↗
32. 10.1023/A:100897312091810.1023/A:1008973120918 ↗
33. Biomaterial aspects of Interpore‐200 porous hydroxyapatite10.1016/S0011-8532(22)02094-8 ↗
34. 10.1108/1355254041056236810.1108/13552540410562368 ↗
35. 10.1006/jmcc.1996.036510.1006/jmcc.1996.0365 ↗
36. 10.1038/nm1095-102410.1038/nm1095-1024 ↗
37. 10.1016/j.archoralbio.2004.05.01210.1016/j.archoralbio.2004.05.012 ↗
38. 10.1083/jcb.151.4.87910.1083/jcb.151.4.879 ↗
39. 10.1016/j.bbrc.2005.06.11610.1016/j.bbrc.2005.06.116 ↗
40. 10.1016/S0014-5793(00)01520-910.1016/S0014-5793(00)01520-9 ↗
41. 10.1016/j.bone.2006.11.00410.1016/j.bone.2006.11.004 ↗
42. 10.1016/j.joms.2005.05.30310.1016/j.joms.2005.05.303 ↗
43. 10.1002/jbm.a.3102410.1002/jbm.a.31024 ↗
44. 10.1002/jbm.1025910.1002/jbm.10259 ↗
45. 10.1016/S0142-9612(96)00162-710.1016/S0142-9612(96)00162-7 ↗
46. 10.1016/0142-9612(91)90053-D10.1016/0142-9612(91)90053-D ↗
47. 10.1002/(SICI)1097-4636(19981205)42:3<357::AID-JBM3>3.0.CO;2-I10.1002/(SICI)1097-4636(19981205)42:3<357::AID-JBM3>3.0.CO;2-I ↗
48. 10.1016/j.biomaterials.2006.05.03110.1016/j.biomaterials.2006.05.031 ↗